Skip to main content
. 2023 Aug 12;41(12):1641–1655. doi: 10.1007/s40273-023-01305-3

Fig. 2.

Fig. 2

One-way sensitivity analysis of chemotherapy versus chemotherapy with bevacizumab. AE adverse event, beva bevacizumab, Chemo chemotherapy, CIs confidence intervals, CHF Swiss Francs, HR hazard ratio, ICER incremental cost-effectiveness ratio, OS overall survival, pem pemetrexed, PFD progression-free disease, PFS progression-free survival, QALY quality-adjusted life-year